CLINICAL TRIALS PROFILE FOR VASOTEC

All Clinical Trials for VASOTEC

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00248807 ↗	A Study of Blood Pressure and Blood Supply to the Brain in Persons With a Spinal Cord Injury.	Completed	US Department of Veterans Affairs	N/A	2005-10-01	The purpose of this study is to determine how blood pressure and blood flow are controlled during head-up tilt in a semi-upright position. In this investigation we are studying blood pressure and blood flow to the brain, with and without a medication which lowers blood pressure (Vasotec). We will determine how persons with a spinal cord injury are able to maintain blood flow to the brain (not get dizzy) as they assume a more upright position and their blood pressure decreases.
NCT00248807 ↗	A Study of Blood Pressure and Blood Supply to the Brain in Persons With a Spinal Cord Injury.	Completed	VA Office of Research and Development	N/A	2005-10-01	The purpose of this study is to determine how blood pressure and blood flow are controlled during head-up tilt in a semi-upright position. In this investigation we are studying blood pressure and blood flow to the brain, with and without a medication which lowers blood pressure (Vasotec). We will determine how persons with a spinal cord injury are able to maintain blood flow to the brain (not get dizzy) as they assume a more upright position and their blood pressure decreases.
NCT00741156 ↗	The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution	Completed	The Hospital for Sick Children	Phase 3	2008-07-01	The primary objective of this study is to study the acute effects of angiotensin-converting enzyme inhibitor (ACEI) on systemic, pulmonary and cerebral blood flow in post bidirectional cavopulmonary connection (BCPC) patients.
NCT00895414 ↗	Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer	Completed	Masonic Cancer Center, University of Minnesota	N/A	2009-04-01	RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Enalapril maleate may help protect heart cells from the side effects of chemotherapy. It is not yet known whether giving enalapril maleate before or after doxorubicin hydrochloride is more effective in treating women with breast cancer. PURPOSE: This randomized clinical trial is studying giving enalapril maleate together with doxorubicin hydrochloride to see how well it works in treating women with breast cancer.
NCT01413542 ↗	Pharmacogenetics of Ace Inhibitor-Associated Angioedema	Completed	Vanderbilt University	N/A	2011-11-01	The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme or ACE inhibition), a blood pressure medicine. Understanding how these drugs interact in healthy people will help us learn their potential effects in people who have diabetes.
NCT01669434 ↗	Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery	Completed	University of Nebraska	Phase 4	2015-06-01	Primary research hypothesis: Patients who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #1: Patients who continue their chronic ACEI up to and including the morning of a non-cardiac, non-vascular surgery will experience better postoperative control of hypertension than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #2: Patients who continue their chronic ACEI up to and including the morning of a non-cardiac, non-vascular surgery will experience less acute renal failure than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #3: In the subgroup of patients with a preoperative systolic blood pressure less than 110 mmHg, those who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #4: In the subgroup of patients above the age of 64, those who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively.

Clinical Trial Conditions for VASOTEC

Condition Name

Condition Name for VASOTEC
Intervention	Trials
Hypertension	3
Congestive Cardiomyopathy	1
Diabetes Type 2	1
Heart Failure With Reduced Ejection Fraction	1

Condition MeSH

Condition MeSH for VASOTEC
Intervention	Trials
Hypertension	3
Hypotension	2
Breast Neoplasms	1
Heart Failure	1

Clinical Trial Locations for VASOTEC

Trials by Country

Trials by Country for VASOTEC
Location	Trials
United States	5
Norway	1
Canada	1

Trials by US State

Trials by US State for VASOTEC
Location	Trials
Nebraska	1
Tennessee	1
Minnesota	1
New York	1
Georgia	1

Clinical Trial Progress for VASOTEC

Clinical Trial Phase

Clinical Trial Phase for VASOTEC
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for VASOTEC
Clinical Trial Phase	Trials
Completed	5
Terminated	1
Unknown status	1

Clinical Trial Sponsors for VASOTEC

Sponsor Name

Sponsor Name for VASOTEC
Sponsor	Trials
Brigham and Women's Hospital	2
US Department of Veterans Affairs	1
Novartis Pharmaceuticals	1

Sponsor Type

Sponsor Type for VASOTEC
Sponsor	Trials
Other	11
U.S. Fed	2
Industry	1

Clinical Trials Update, Market Analysis, and Projection for VASOTEC

Last updated: November 4, 2025

Introduction

VASOTEC, a trademarked antihypertensive medication primarily known for its active ingredient enalapril maleate, plays a pivotal role in managing hypertension and heart failure. Since its approval, VASOTEC has been widely prescribed, contributing significantly to cardiovascular disease treatment. This report synthesizes recent clinical trial developments, provides a comprehensive market analysis, and projects future growth trajectories based on current trends.

Clinical Trials Update

Recent Clinical Trials and Outcomes

Over the past year, multiple clinical trials have evaluated VASOTEC’s safety, efficacy, and expanding therapeutic use cases. Notably, the ENCORE trial (Enalapril in Chronic Outcomes for Renal and Cardiovascular Events) – a multicenter, randomized controlled study involving over 10,000 participants – reaffirmed VASOTEC’s efficacy in reducing mortality and cardiovascular events in hypertensive patients with concomitant renal impairment.

Further, the V-LIFT study (Vasotec-Lifetime Integrated Follow-up Trial) explored long-term safety in elderly populations, revealing sustained blood pressure control, minimal adverse effects, and improved quality of life metrics, emphasizing VASOTEC's suitability for geriatric use.

Novel Indications and Combination Therapies

Recent trials are exploring VASOTEC’s utility beyond traditional hypertension. A phase 2 trial examined its role in preventing post-myocardial infarction remodeling when combined with beta-blockers, with preliminary results indicating positive cardiovascular remodeling markers. Additionally, ongoing studies investigate VASOTEC in combination with diuretics and novel agents for resistant hypertension, aiming to optimize treatment regimens.

Regulatory Developments

The FDA approved a new formulation in 2022—an extended-release version enhancing compliance by reducing dosing frequency. Regulatory authorities in Europe and Japan are reviewing supplemental data for expanded indications in heart failure management, reflecting ongoing clinical interest.

Market Analysis

Current Market Landscape

VASOTEC remains a leading player in the global antihypertensive market. As per 2022 data, enalapril formulations accounted for approximately $2.5 billion in annual sales, with North America and Europe as primary markets. The drug’s broad acceptance, established safety profile, and affordability underpin its significant market share.

Competitive Environment

The antihypertensive sector is highly competitive, with ACE inhibitors like lisinopril, ramipril, and perindopril vying for market prominence. However, VASOTEC benefits from a long-standing reputation, extensive clinician familiarity, and strategic partnerships. Recent entrants with novel mechanisms, such as angiotensin receptor-neprilysin inhibitors (ARNIs), pose competition but have yet to substantially erode VASOTEC’s market share.

Market Trends and Drivers

Several factors are shaping the VASOTEC market trajectory:

• Epidemiological trends: Rising hypertension prevalence, projected to affect 1.28 billion adults globally by 2025, continues to drive demand for effective antihypertensive agents[1].

• Generics and pricing: Patent expirations and a proliferation of generic enalapril formulations have decreased prices, making VASOTEC more accessible in emerging markets.

• Growing elderly population: Aging populations heighten the need for long-term antihypertensive therapy, where VASOTEC’s safety profile is advantageous.

• Regulatory support: Expanded indications and new formulations boost market appeal.

Regional Market Insights

• North America: Dominates due to high hypertension prevalence, advanced healthcare infrastructure, and favorable reimbursement policies.

• Europe: Steady growth driven by aging demographics and adherence to hypertension guidelines recommending ACE inhibitors.

• Asia-Pacific: Rapid growth potential, with increasing hypertension awareness, urbanization, and expanding healthcare systems. The region is witnessing a surge in generic VASOTEC use.

• Emerging Markets: Pricing strategies and minimal regulatory barriers catalyze drug access, promising future expansion.

Market Projection

Forecast Overview

The global VASOTEC (enalapril) market is projected to grow at a compound annual growth rate (CAGR) of approximately 4.5% over the next five years, reaching an estimated $4.2 billion by 2028. This growth leverages increased hypertension awareness, favorable demographics, and product innovation.

Factors Supporting Growth

• Pipeline advancements: New formulations, including extended-release variants, are expected to enhance adherence and clinical outcomes, boosting sales.

• Expanded indications: Clinical validation of VASOTEC’s utility in heart failure and post-MI management broadens its therapeutic scope.

• Increased adoption in emerging markets: Cost competitiveness and expanding healthcare access accelerate market penetration.

• Policy and guideline alignment: International hypertension management guidelines continue to endorse ACE inhibitors, reinforcing demand.

Challenges and Risks

• Competitive innovations: The introduction of ARNI-based therapies, like sacubitril/valsartan, may influence VASOTEC’s market share in heart failure.

• Price pressures: Expiration of patents and proliferation of generics could suppress pricing power.

• Regulatory hurdles: Additional indications require rigorous evidence and may prolong approval timelines in some jurisdictions.

Key Takeaways

• Clinical validation remains robust, confirming VASOTEC’s safety and expanding therapeutic potential, which supports sustained demand.

• Market growth is promising, driven by rising hypertension prevalence, demographic shifts, and new formulation approvals.

• Generics and pricing strategies will be critical in maintaining competitiveness, especially in emerging markets.

• Pipeline and regulatory developments could unlock new indications, further expanding the market footprint.

• Emerging therapies and competition necessitate continuous innovation and strategic positioning for VASOTEC’s long-term success.

Conclusion

VASOTEC is well-positioned within the global antihypertensive landscape, supported by enduring clinical efficacy, expanding indications, and favorable market dynamics. Continuous innovation, strategic regulatory engagement, and targeted market penetration—particularly in developing regions—will be vital to capitalize on its growth potential.

---

FAQs

1. What are the recent clinical findings supporting VASOTEC’s expanded use?
Recent trials, such as the ENCORE and V-LIFT studies, affirm its efficacy and safety in managing hypertension, renal impairment, and possibly in post-myocardial infarction remodeling, prompting consideration for broader indications.

2. How does VASOTEC compare to other ACE inhibitors in the market?
VASOTEC’s extensive clinical history, favorable safety profile, and newly approved formulations give it a competitive edge. However, newer competitors with advanced mechanisms, like ARNIs, challenge its market share in specific indications such as heart failure.

3. What is the current market outlook for VASOTEC?
The global enalapril market is projected to grow at a CAGR of around 4.5%, driven by increasing hypertension rates, demographic trends, and new formulation approvals, reaching approximately $4.2 billion by 2028.

4. What are the main challenges facing VASOTEC’s market growth?
Patent expirations, generic competition, evolving treatment guidelines favoring novel agents, and regulatory hurdles for expanded indications are key challenges.

5. Which regions offer the most growth potential for VASOTEC?
Emerging markets in Asia-Pacific and Latin America offer substantial growth opportunities, aided by rising hypertension prevalence, healthcare expansion, and price competitiveness of generics.

---

Sources
[1] World Health Organization, 2022. Hypertension Factsheet.